Thomas Stoddard

Title: Innovations of Thomas Stoddard

Introduction

Thomas Stoddard is an accomplished inventor based in St. Louis Park, MN (US). He holds a total of four patents, showcasing his significant contributions to the field of plant biotechnology. His work primarily focuses on developing methods for creating plants that can produce therapeutic polypeptides for human and animal administration.

Latest Patents

Stoddard's latest patents include innovative methods for producing mutant plants or cells with reduced xylosyltransferase (XylT) and fucosyltransferase (FucT) activity. These materials and methods are designed to facilitate the creation of plant varieties that are suitable for producing therapeutic polypeptides. His work involves using TAL effector endonuclease-induced mutations in genes encoding XylT and FucT. Another notable patent details a method for making Nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases, further emphasizing his focus on therapeutic applications in plant biotechnology.

Career Highlights

Throughout his career, Stoddard has made significant strides in the field of genetic engineering and plant biotechnology. His innovative approaches have led to advancements that could potentially revolutionize the production of therapeutic proteins. His expertise in utilizing endonucleases for targeted mutations has positioned him as a key figure in this area of research.

Collaborations

Stoddard has collaborated with notable professionals in the field, including Luc Mathis and Daniel F Voytas. These collaborations have likely contributed to the success and impact of his research endeavors.

Conclusion

Thomas Stoddard's work in plant biotechnology and genetic engineering has led to important innovations that hold promise for therapeutic applications. His patents reflect a commitment to advancing the field and improving the production of essential therapeutic compounds.